Tag: #Global Trends

Aktis Oncology has set a high bar for the 2026 biotech financial calendar by raising $318 million in its initial... Read more

New data from the Phase 3b Together-PsA clinical trial indicates that the concurrent administration of ixekizumab (an IL-17A antagonist) and... Read more

Economic experts are offering mixed forecasts regarding Nestlé's potential losses following its global baby formula recall. According to analyses from... Read more

Pharmaceutical giant Eli Lilly has entered into a new research and licensing agreement with Nimbus Therapeutics. The partnership aims to... Read more

On January 8, 2026, the U.S. Food and Drug Administration (FDA) granted approval for a new 2-gram (g) formulation of... Read more

New data from the phase 3 Herizon-Gea-01 clinical trial signals a potential paradigm shift in the first-line treatment of HER2-positive... Read more

The German chemical and pharmaceutical giant Bayer has filed separate lawsuits against Moderna, Johnson & Johnson (J&J), and the Pfizer-BioNTech... Read more

Clarivate’s annual "Drugs to Watch 2026" report has identified 11 potential blockbusters, with Eli Lilly’s cardiometabolic therapies taking center stage.... Read more

The pharmaceutical giant Amgen has finalized an agreement to purchase Dark Blue Therapeutics, a UK-based biotechnology firm. The total valuation... Read more